SeaSpine Stock Forecast, Price & News

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

Is SeaSpine a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SeaSpine stock.
View analyst ratings for SeaSpine or view top-rated stocks.

How has SeaSpine's stock been impacted by Coronavirus?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPNE shares have increased by 11.4% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19.

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for SeaSpine.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) announced its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.17. The medical equipment provider earned $46.45 million during the quarter, compared to the consensus estimate of $45.66 million. SeaSpine had a negative net margin of 25.18% and a negative trailing twelve-month return on equity of 20.88%. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the company earned ($0.24) earnings per share.
View SeaSpine's earnings history.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine issued an update on its fourth quarter 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54 million-$55 million, compared to the consensus revenue estimate of $58.61 million.

What price target have analysts set for SPNE?

5 Wall Street analysts have issued 1-year price objectives for SeaSpine's shares. Their forecasts range from $20.00 to $100.00. On average, they anticipate SeaSpine's stock price to reach $37.80 in the next twelve months. This suggests a possible upside of 216.3% from the stock's current price.
View analysts' price targets for SeaSpine or view top-rated stocks among Wall Street analysts.

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:

• Keith C. Valentine, President, Chief Executive Officer & Director
• John J. Bostjancic, Chief Financial Officer, Treasurer & Senior VP
• Chris Shen, VP-Information Technology & Customer Experience
• Frank Vizesi, Vice President-Clinical Affairs
• Patrick L. Keran, Secretary, Senior Vice President & General Counsel

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine CEO Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among SeaSpine's employees.

Who are some of SeaSpine's key competitors?

Some companies that are related to SeaSpine include Atrion (ATRI), Silk Road Medical (SILK), Paragon 28 (FNA), Bioventus (BVS), Alphatec (ATEC), Treace Medical Concepts (TMCI), LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS), Intersect ENT (XENT), Cerus (CERS), Pulmonx (LUNG), AngioDynamics (ANGO), Longview Acquisition Corp. II (LGV), Inovio Pharmaceuticals (INO) and Procept BioRobotics (PRCT).
View all of SPNE's competitors.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a number of institutional and retail investors. Top institutional investors include HighMark Wealth Management LLC (0.82%). Company insiders that own SeaSpine stock include Beau Standish, John B Henneman III, Renee Gaeta and Richard E Caruso.
View institutional ownership trends for SeaSpine.

Which institutional investors are buying SeaSpine stock?

SPNE stock was acquired by a variety of institutional investors in the last quarter, including HighMark Wealth Management LLC.
View insider buying and selling activity for SeaSpine or or view top insider-buying stocks.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $11.95.

How much money does SeaSpine make?

SeaSpine has a market capitalization of $435.48 million and generates $154.35 million in revenue each year. The medical equipment provider earns $-43.18 million in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does SeaSpine have?

SeaSpine employs 421 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

Where are SeaSpine's headquarters?

SeaSpine is headquartered at 5770 ARMADA DRIVE, CARLSBAD CA, 92008.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at (760) 727-8399 or via email at [email protected].